Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-molecular-weight heparin in vascular intrauterine growth restriction
2016-000424-25Phase 3Completed
- Sponsor
- CHU Saint-Etienne
- Start
- Feb 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised trial of enoxaparin in intrauterine growth restriction (IUGR) (2 arms), sponsored by CHU Saint-Etienne. Primary endpoint: Proportion of newborns with birth weight below 10th percentile. Started Feb 2019; status: completed.
02
Drugs
enoxaparin
03
Conditions
intrauterine growth restriction (IUGR)
Beyond the preview
Go deeper on 2016-000424-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-000424-25.